Dipexium Pharmaceuticals Inc Stock Nasdaq

US25456J1043

OTC Markets Traded

Days

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Latest news : Dipexium Pharmaceuticals Inc

29/09/23	PLx Pharma Winddown Corp. Went Out of Business	CI
14/09/23	First Amended Combined Liquidation Plan and Disclosure Statement Approved for PLx Pharma Winddown Corp.	CI
28/08/23	First Motion for Exclusivity Period Extension Approved For PLx Pharma Winddown Corp.	CI
10/08/23	First Motion for Exclusivity Period Extension Filed by PLx Pharma Winddown Corp.	CI
28/07/23	First Amended Disclosure Statement and Related Plan on Interim Basis Approved for PLx Pharma Winddown Corp.	CI
26/07/23	First Amended Combined Liquidation Plan and Disclosure Statement Filed by PLx Pharma Winddown Corp.	CI
08/07/23	Plx Pharma Winddown Corp. Announces Resignation of Natasha Giordano as Chief Executive Officer	CI
08/07/23	Plx Pharma Winddown Corp. Announces Resignation of Rita Oâ€™Connor as Chief Financial Officer	CI
08/07/23	Plx Pharma Winddown Corp. Announces Executive Changes	CI
07/07/23	Combined Disclousre Statement and Liquidation Plan Filed by PLx Pharma Winddown Corp.	CI
25/05/23	Motion for Asset Sale Approved for PLx Pharma Winddown Corp.	CI
19/05/23	Notice for Auction Cancellation Filed PLx Pharma Winddown Corp.	CI
10/05/23	Bidding Procedure Approved for PLx Pharma Inc.	CI

More news

Analysts' recommendations: Dipexium Pharmaceuticals Inc

15/08/22	Oppenheimer Downgrades PLx Pharma to Perform From Outperform, Removes $11 Price Target	MT
15/08/22	JMP Securities Downgrades PLx Pharma to Market Perform From Market Outperform	MT
16/05/22	Raymond James Adjusts PLx Pharma's Price Target to $10 from $12, Keeps Outperform Rating	MT
14/03/22	Oppenheimer Adjusts PLx Pharma Price Target to $16 From $22, Maintains Outperform Rating	MT
14/03/22	Raymond James Adjusts PLx Pharma Price Target to $12 From $14, Maintains Outperform Rating	MT

More recommendations

Press Releases: Dipexium Pharmaceuticals Inc

27/05/23	PLx Pharma : Material Agreement - Form 8-K	PU
14/04/23	PLx Pharma : Bankruptcy - Form 8-K	PU
14/04/23	PLX PHARMA INC. : Bankruptcy or Receivership, Financial Statements and Exhibits (form 8-K)	AQ
13/04/23	PLX PHARMA INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/23	PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets	AQ

More press releases

Managers and Directors: Dipexium Pharmaceuticals Inc

Manager	Title	Age	Since
Lawrence Perkins PRN	Corporate Officer/Principal	49	07/03/2023
John Halloran PRN	Corporate Officer/Principal	-	07/03/2023
Thomas L. Long PRN	Corporate Officer/Principal	-	19/09/2017

Director	Title	Age	Since
Michael Valentino CHM	Chairman	72	01/07/2011
Gary Balkema BRD	Director/Board Member	71	01/01/2016
Bob Casale BRD	Director/Board Member	67	01/02/2016

More insiders

PLx Pharma Winddown Corp., formerly PLx Pharma Inc., is a commercial-stage drug delivery platform technology company. The Company is focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent-protected PLxGuard technology. The Company has two Food and Drug Administration (FDA) approved products, VAZALORE 81 mg and VAZALORE 325 mg (VAZALORE), which are liquid-filled aspirin capsules for over-the-counter distribution (OTC). The Company markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation. It also screens additional compounds outside the NSAID category for possible development using its PLxGuard drug delivery platform.

Employees

Sector

More about the company